Thousands of people across 15 counties in Kenya, who are marked for the rollout of an HIV prevention drug, Lenacapavir, will now pay Sh7,800 per patient annually under the latest Global Fund–supported arrangement, some Sh2,630 more than the price secured last year through the Gates Foundation–Hetero Labs access partnership.
In September, the Gates Foundation and Indian pharmaceutical company Hetero Labs announced that low- and middle-income countries, including Kenya, would have access to Lenacapavir at $40, approximately Sh5,170, per person per year.
